Asciminib appeared to have clinical activity in a population of heavily pretreated patients with chronic myeloid leukemia, including those with a T315I mutation.
Results of LAST, the largest study on TKI discontinuation, support using patient-reported outcomes when monitoring remission and symptoms in patients who discontinue TKI therapy.
Patients received 50 mg dasatinib daily and demonstrated 2-year rates of overall and event-free survival of 100%.
This study assessed levels of adherence to antihypertensive, lipid-lowering, and antidiabetic therapy in patients initiating oral oncology therapy for a hematologic cancer.
If crowdfunding doesn’t work, here’s how oncologists can help patients with financial toxicity.